


PRODUCT INFORMATION



Candesartan

Item No. 9003239

CAS Registry No.: 139481-59-7
Formal Name: 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid
Synonyms: Candesartan M1, CV-11974
MF: C₂₄H₂₀N₆O₃
FW: 440.5
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Candesartan is supplied as a solid. A stock solution may be made by dissolving the candesartan in the solvent of choice, which should be purged with an inert gas. Candesartan is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of candesartan in these solvents is approximately 15 and 20 mg/ml, respectively.

Candesartan is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, candesartan should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Candesartan has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Candesartan is an antagonist of the angiotensin II type 1 (AT₁) receptor (K_is = 0.17, 0.12, and 0.12 nM for recombinant human AT₁, rat AT_{1A}, and rat AT_{1B} receptors, respectively) and an active metabolite of the prodrug candesartan cilexetil (Item No. 10489).¹ It is selective for AT₁ over AT₂ receptors (K_i = 26,500 nM for the recombinant human AT₂ receptor). It inhibits angiotensin II-induced contraction of isolated rabbit aortic strips and increases in blood pressure in rats following intravenous administration (ID₅₀ = 0.033 mg/kg).² Formulations containing candesartan have been used in the treatment of hypertension and heart failure.

References

1. Inada, Y., Nakane, T., and Chiba, S. Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors. *Fundam. Clin. Pharmacol.* **16**(4), 317-323 (2002).
2. Shibouta, Y., Inada, Y., Ojima, M., et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). *J. Pharmacol. Exp. Ther.* **266**(1), 114-120 (1993).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/03/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM